No Data
No Data
Hendy Pharmaceuticals (301211.SZ) plans to pay 4.8 yuan for 10 shares to be deducted from interest on May 27
Hendy Pharmaceuticals (301211.SZ) announced that the company's 2023 profit distribution will be distributed to all shareholders for every 10 shares...
Biocause Heilen Pharmaceutical's Cardiovascular Drug Passes Chinese Drug Regulator's Evaluation
Hubei Biocause Heilen Pharmaceutical's (SHE:301211) torsemide tablets passed the generic drug quality and efficacy consistency evaluation of China's National Medical Products Administration, the comp
Hendy Pharmaceuticals (301211.SZ): Torasemide tablets pass generic drug consistency evaluation
Gelonghui, May 16 | Hendi Pharmaceutical (301211.SZ) announced that the company recently received the “Drug Supplement Application Approval Notice” for torasemide tablets (hereinafter referred to as “drugs”) approved and issued by the State Drug Administration. The company's torasemide tablets are cardiovascular drugs, mainly used for edema associated with high blood pressure, chronic congestive heart failure, liver cirrhosis, ascites, and nephrotic syndrome.
Hendy Pharmaceuticals (301211.SZ): Currently not involved in the field of synthetic biology
Gelonghui, May 6 | Hendi Pharmaceutical (301211.SZ) said on the investor interactive platform that the company is mainly engaged in R&D, production and sales of chemical raw materials (including intermediates) and pharmaceutical products, and can also provide contract R&D and production services (CDMO) according to customer needs. Contract R&D and production services (CDMO) include intermediates, key starting materials, and APIs to meet the needs of customers for process R&D, pilot scale-up, commercial production, method verification and registration at all stages from pre-clinical to commercialization. The company is currently not involved in the field of synthetic biology.
Hubei Biocause Heilen Pharmaceutical (SZSE:301211) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Hubei Biocause Heilen Pharmaceutical Co., Ltd.'s (SZSE:301211) robust earnings report didn't manage to move the market for its stock. Our analysis suggests that shareholders have noticed something co
Hendy Pharmaceuticals (301211.SZ) announced first-quarter results, net profit of 37.3816 million yuan, a decrease of 6.37%
Hendy Pharmaceuticals (301211.SZ) released its report for the first quarter of 2024, achieving operating income of 1.3 during the reporting period...
No Data